今日の臨床サポート

非アルコール性脂肪肝炎(NASH)

関連論文:
img  21:  Weight reduction for non-alcoholic fatty liver disease.
 
著者: Lijun Peng, Jiyao Wang, Feng Li
雑誌名: Cochrane Database Syst Rev. 2011 Jun 15;(6):CD003619. doi: 10.1002/14651858.CD003619.pub3. Epub 2011 Jun 15.
Abstract/Text BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is becoming a wide spread liver disease. The present recommendations for treatment are not evidence-based. Some of them are various weight reduction measures with diet, exercise, drug, or surgical therapy.
OBJECTIVES: To assess the benefits and harms of intended weight reduction for patients with NAFLD.
SEARCH STRATEGY: We searched The Cochrane Hepato-Biliary Group Controlled Trials Register, The Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, PubMed, EMBASE, Science Citation Index Expanded, Chinese Biomedicine Database, and ClinicalTrials.gov until February 2011.
SELECTION CRITERIA: We included randomised clinical trials evaluating weight reduction with different measures versus no intervention or placebo in NAFLD patients.
DATA COLLECTION AND ANALYSIS: We extracted data independently. We calculated the odds ratio (OR) for dichotomous data and calculated the mean difference (MD) for continuous data, both with 95% confidence intervals (CI).
MAIN RESULTS: The review includes seven trials; five on aspects of lifestyle changes (eg, diet, physical exercise) and two on treatment with a weight reduction drug 'orlistat'. In total, 373 participants were enrolled, and the duration of the trials ranged from 1 month to 1 year. Only one trial on lifestyle programme was judged to be of low risk of bias. We could not perform meta-analyses for the main outcomes as they were either not reported or there were insufficient number of trials for each outcome to be meta-analysed. We could meta-analyse the available data for body weight and body mass index only. Adverse events were poorly reported.
AUTHORS' CONCLUSIONS: The sparse data and high risk of bias preclude us from drawing any definite conclusion on lifestyle programme or orlistat for treatment of NAFLD. Further randomised clinical trials with low risk of bias are needed to test the beneficial and harmful effects of weight reduction for NAFLD patients. The long-term prognosis of development of fibrosis, mortality, and quality of life should be studied.

PMID 21678341  Cochrane Database Syst Rev. 2011 Jun 15;(6):CD003619. doi: 10.1002/14651858.CD003619.pub3. Epub 2011 Jun 15.
戻る

さらなるご利用にはご登録が必要です。

こちらよりご契約または優待日間無料トライアルお申込みをお願いします。

(※トライアルご登録は1名様につき、一度となります)


ご契約の場合はご招待された方だけのご優待特典があります。

以下の優待コードを入力いただくと、

契約期間が通常12ヵ月のところ、14ヵ月ご利用いただけます。

優待コード: (利用期限:まで)

ご契約はこちらから